These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36286834)

  • 1. [Effect of vitamin D receptor activators on serum Klotho levels in 3b-4 stages chronic кidney disease patients: a prospective randomized study].
    Milovanova LY; Beketov VD; Milovanova SY; Taranova MV; Kozlov VV; Pasechnik AI; Reshetnikov VA; Androsova TV; Kalashnikov MV
    Ter Arkh; 2021 Jun; 93(6):679-684. PubMed ID: 36286834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Decreased Serum Levels of Klotho Protein in Chronic Kidney Disease Patients: Clinical Imortance].
    Milovanova LY; Mukhin NA; Kozlovskaya LV; Milovanov YS; Kiyakbaev GG; Rogova IV; Lebedeva MV; Androsova TV; Milovanova SY; Gil AY; Taranova MV
    Vestn Ross Akad Med Nauk; 2016; 71(4):288-96. PubMed ID: 29297646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do the benefits of using calcitriol and other vitamin D receptor activators in patients with chronic kidney disease outweigh the harms?
    Toussaint ND; Damasiewicz MJ
    Nephrology (Carlton); 2017 Mar; 22 Suppl 2():51-56. PubMed ID: 28429545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease].
    Milovanova LY; Milovanov YS; Kudryavtseva DV; Markina MM; Milovanova SY; Kozlovskaya LV; Lebedeva MV; Beketov VD; Moiseev SV; Mukhin NA; Fomin VV; Svistunov AA
    Ter Arkh; 2015; 87(6):10-16. PubMed ID: 26281189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of essential amino acid кetoanalogues and protein restriction diet on morphogenetic proteins (FGF-23 and Кlotho) in 3b-4 stages chronic кidney disease patients: a randomized pilot study.
    Milovanova L; Fomin V; Moiseev S; Taranova M; Milovanov Y; Lysenko Kozlovskaya L; Kozlov V; Kozevnikova E; Milovanova S; Lebedeva M; Reshetnikov V
    Clin Exp Nephrol; 2018 Dec; 22(6):1351-1359. PubMed ID: 29948444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.
    Pavik I; Jaeger P; Ebner L; Wagner CA; Petzold K; Spichtig D; Poster D; Wüthrich RP; Russmann S; Serra AL
    Nephrol Dial Transplant; 2013 Feb; 28(2):352-9. PubMed ID: 23129826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [MORPHOGENETIC PROTEINS--FIBROBLAST GROWTH FACTOR AND KLOTHO, IN THE SERA OF PATIENTS WITH CHRONIC RENAL DISEASE].
    Milovanova LY; Kozlovskaya LV; Markina MM; Milovanova SY; Borisov AA; Mukhin NA; Fomin VV; Moiseev SV
    Klin Med (Mosk); 2015; 93(12):32-8. PubMed ID: 27149811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet.
    Lau WL; Leaf EM; Hu MC; Takeno MM; Kuro-o M; Moe OW; Giachelli CM
    Kidney Int; 2012 Dec; 82(12):1261-70. PubMed ID: 22932118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [EVALUATION OF CARDIOVASCULAR RISKS WITH THE USE OF MORPHOGENETIC KLOTHO PROTEIN IN PATIENTS WITH CHRONIC RENAL DISEASE].
    Mukhin NA; Milovanova LY; Fomin VV; Kozlovskaya LV; Taranova MV; Androsova TV; Borisov AA
    Klin Med (Mosk); 2017; 95(3):272-7. PubMed ID: 30303650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Impact of anemia correction on the production of the circulating morphogenetic protein α-Klotho in patients with Stages 3B-4 chronic kidney disease: A new direction of cardionephroprotection].
    Milovanov YS; Mukhin NA; Kozlovskaya LV; Milovanova SY; Markina MM
    Ter Arkh; 2016; 88(6):21-25. PubMed ID: 27296257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New markers of cardio-renal links in chronic kidney disease].
    Milovanova LIu; Milovanov IuS; Kozlovskaia LV; Mukhin NA
    Ter Arkh; 2013; 85(6):17-24. PubMed ID: 23866594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between paricalcitol and active non-selective vitamin D receptor activator for secondary hyperparathyroidism in chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.
    Cai P; Tang X; Qin W; Ji L; Li Z
    Int Urol Nephrol; 2016 Apr; 48(4):571-84. PubMed ID: 26748501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH ≤ 150 pg/mL: results of the Italian FARO Survey.
    Cozzolino M; Brancaccio D; Cannella G; Messa P; Gesualdo L; Marangella M; LoDeserto C; Pozzato M; Rombolà G; Costanzo AM; di Luzio Paparatti U; Mazzaferro S;
    Nephrol Dial Transplant; 2012 Sep; 27(9):3588-94. PubMed ID: 22523119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of combined vitamin D receptor activator and lanthanum carbonate on serum fibroblast growth factor 23 level in predialysis patients (CVD-LAF study): design and method.
    Ito E; Inaguma D; Koide S; Takahashi K; Hayashi H; Hasegawa M; Yuzawa Y
    Clin Exp Nephrol; 2018 Dec; 22(6):1309-1314. PubMed ID: 29748907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association between soluble klotho and cardiovascular parameters in chronic kidney disease: results from the KNOW-CKD study.
    Kim HJ; Kang E; Oh YK; Kim YH; Han SH; Yoo TH; Chae DW; Lee J; Ahn C; Oh KH
    BMC Nephrol; 2018 Mar; 19(1):51. PubMed ID: 29506503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease
.
    Yin C; Cheng C; Wang J; Zhang L; Purrunsing Y; Yang G; Zeng M; Huang H; Ren W; Ye Y; Ma H; Xing C; Wang N
    Clin Nephrol; 2020 Feb; 93(2):65-76. PubMed ID: 31793871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease-a prospective cohort study.
    Tranæus Lindblad Y; Olauson H; Vavilis G; Hammar U; Herthelius M; Axelsson J; Bárány P
    Pediatr Nephrol; 2018 Jan; 33(1):147-157. PubMed ID: 28795324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A decreased level of serum soluble Klotho is an independent biomarker associated with arterial stiffness in patients with chronic kidney disease.
    Kitagawa M; Sugiyama H; Morinaga H; Inoue T; Takiue K; Ogawa A; Yamanari T; Kikumoto Y; Uchida HA; Kitamura S; Maeshima Y; Nakamura K; Ito H; Makino H
    PLoS One; 2013; 8(2):e56695. PubMed ID: 23431388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of keto/amino acids and a low-protein diet on the nutritional status of patients with Stages 3B-4 chronic kidney disease].
    Milovanova SY; Milovanov YS; Taranova MV; Dobrosmyslov IA
    Ter Arkh; 2017; 89(6):30-33. PubMed ID: 28745686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.